Taconic's lab site sells at apartment-feedstock pricing

Taconic Partners has sold the Upper East Side site it assembled for a research lab to LCOR, an apartment developer that paid $73 million for 309 East 94th Street, according to city records filed Thursday, a slight premium to the $70 million all-cash price Taconic and its joint venture partners paid the Karten family in December 2021 for the 87,000-square-foot assemblage between First and Second avenues.

What the joint venture intended to put there in the interim was 200,000 square feet of Class A research space across eight stories — Iron Horse Labs, pitched on its proximity to Rockefeller University, Mount Sinai Medical Center and NYC Health + Hospitals. Elevate Research Properties, a Taconic subsidiary, held the site alongside Nuveen Real Estate and Flatiron Equities; Ares Commercial Real Estate provided a $79 million construction loan in 2022, and construction began in 2023. The site today, according to The Real Deal, still holds what it held before the plans — a five-story loft-style building, a two-story garage and an auto shop — but the coverage does not say how far the work advanced, how much of the Ares facility was drawn, or who brokered the sale.

Set the price against the debt and the deal reads less like an exit than a resolution: $73 million across 87,000 square feet works out to roughly $840 a foot, $6 million below the face amount of the $79 million construction loan that was supposed to build the lab. The nominal gain over the 2021 basis is $3 million, earned across four years and nine months of entitlement, design and debt service, and interest on even a fraction of a $79 million facility clears that in short order — which suggests the joint venture's economics are worse than the headline price implies. The caveats are real: neither the full cost basis nor how the loan was resolved is public, and the second of those is where the actual economics of the 2021 underwriting sit.

New York's lab demand is the backdrop to all of it, with leasing volume in the city's life sciences sector falling 84 percent in the first quarter of 2026 from the previous quarter, according to CBRE data — a quarter-over-quarter reading sharp enough to distrust on its own and consistent with what a long hold looks like when an entitlement outlives the market that justified it. Iron Horse Labs was to deliver into a market that has since gone quiet, on a parcel that still has a garage and an auto shop on it.

The 94th Street trade is Taconic's second Manhattan lab exit in three months, and the buyer profile repeats: in July the firm sold West End Labs at 125 West End Avenue for $188 million to Bill Ackman's Pershing Square Foundation, part of Taconic's 3.4-acre West End Campus, and neither buyer is a life science operator. One is an apartment developer, the other a philanthropic foundation with a horizon long enough to look through a soft leasing market, a pairing that says something about who is left at the table when unbuilt lab space comes up for bid.

LCOR's plans for the parcel are not disclosed, but the firm's shape is familiar — apartment development along the East Coast, with a recent entry into South Florida's residential market — and an 87,000-square-foot site between First and Second avenues that comes with a five-story loft building, a garage and an auto shop to clear is a demolition-and-rebuild program rather than a repositioning, the office-to-apartment feedstock trade in a different market. The Norwalk sale in August ran the same play, with a joint venture planning 286 apartments on two former office buildings and a $75.5 million OZK construction loan underwriting the next use. At 309 East 94th Street the order is reversed: the construction debt came first and financed the use that did not happen.

Multifamily capital is clearing at public data points now, and buyers are underwriting operations rather than rent growth, so an $840-a-foot basis on Upper East Side land, committed to a program that runs demolish, build, lease, fits that description exactly, because no rent-growth assumption arrives in time to rescue the underwriting. Where the facts cut against the house view is the premium: a market underwriting operations would be expected to pay less for lab-entitled dirt than a lab developer would, and LCOR paid $3 million more than the 2021 basis for a parcel whose lab alternative stopped before it delivered. Read it the other way and the conclusion holds — the floor under this assemblage is residential land value, and at $73 million that floor sits above what the lab market would clear it at, so long as apartment land outbids lab entitlement on the same parcel.

For the rest of the market, $840 a foot is the marker: an apartment builder's number, paid for land underwritten as a lab, and the figure the next lab-entitled Manhattan parcel gets measured against. The number still missing is how the Ares facility was resolved, and that one will tell lenders what a stalled lab underwriting is actually worth.